Safety Study of FluMist With and Without Ampligen

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

August 31, 2015

Conditions
Influenza, Human
Interventions
DRUG

Poly I:Poly C12U 50 ug

Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days

DRUG

Poly I:Poly C12U 200 ug

Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days

DRUG

Poly I:Poly C12U 500 ug

Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days

DRUG

Poly I:Poly C12U 1250 ug

Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days

DRUG

Placebo

Placebo; 3 doses; nasal administration every 28 days

DRUG

FluMist

FluMist 0.2 ml; 3 doses; nasal administration every 28 days

Trial Locations (1)

35294

The University of Alabama at Birmingham, Birmingham

Sponsors
All Listed Sponsors
lead

AIM ImmunoTech Inc.

INDUSTRY